CatalystWire
← Back to feed

Hemogenyx Pharmaceuticals

HEMO · Main Market · Health Care · mcap £48m today

All announcements

All RNS · 26 Key events · 12
  1. 30 Sep 26
    Total Voting Rights
    RNS 9797580 ↗
  2. 28 Sep 26
    Half-year Results

    Interim Results for the period ended 30 June 2026

    RNS 9792627 ↗
  3. 03 Sep 26
    Exercise of Warrants and Issue of Equity

    Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces that it has received notices to exercise warrants over 96,825 new ordinary shares in the Company (the "Warrant Shares").

    RNS 9752806 ↗
  4. 11 Aug 26
    Collaboration with Cellin Technologies

    Hemogenyx Pharmaceuticals Signs Definitive Collaboration Agreement with Cellin Technologies for Manufacturing and Commercialization of HG-CT-1 CAR-T Therapy in Estonia

    RNS 9714349 ↗
  5. 29 Jul 26
    Collaboration and Company Update

    Collaboration with Vilnius University Hospital Santaros Klinikos on HG-CT-1 Clinical Application and Research

    RNS 9692329 ↗
  6. 01 Jul 26
    Result of AGM
    RNS 9645631 ↗
  7. 05 Jun 26
    Notice of AGM
    RNS 9603088 ↗
  8. 29 May 26
    Grant of Options and Extension of Warrant Term
    RNS 9591976 ↗
  9. 30 Apr 26
    Final Results

    Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces its final audited results for the year ended 31 December 2025.

    RNS 9547533 ↗
  10. 28 Apr 26
    Institutional Fundraise

    Hemogenyx Secures £3,000,000 to accelerate its Phase 1 Clinical Trials and initiate early commercialization of HG-CT-1

    RNS 9540479 ↗
  11. 14 Apr 26
    Annual IND Report with FDA

    Hemogenyx Pharmaceuticals Files Annual IND Report with FDA for HG-CT-1 CAR-T Therapy for AML

    RNS 9518094 ↗
  12. 31 Mar 26
    Tech Transfer Completion and Clinical Trial Update

    Hemogenyx Pharmaceuticals plc (LSE: HEMO), a biopharmaceutical company focused on the development of innovative therapies for the treatment of blood diseases, is pleased to provide the following update on its HG-CT-1 CAR-T cell therapy program for...

    RNS 9501187 ↗
  13. 27 Feb 26
    Total Voting Rights
    RNS 9450705 ↗
  14. 24 Feb 26
    Holding(s) in Company
    RNS 9443384 ↗
  15. 23 Feb 26
    Exercise of Warrants and Issue of Equity

    Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces that it has received notices to exercise warrants over 50,841 new ordinary shares in the Company (the "Warrant Shares").

    RNS 9441293 ↗
  16. 10 Feb 26
    Issue of Equity - Correction
    RNS 9424349 ↗
  17. 10 Feb 26
    Issue of Equity
    RNS 9422459 ↗
  18. 30 Jan 26
    Total Voting Rights
    RNS 9394680 ↗
  19. 12 Jan 26
    Holding(s) in Company
    RNS 9346324 ↗
  20. 22 Dec 25
    Update on Admission of Shares

    Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, provides an update to the admission of new ordinary shares as announced on 18 December 2025.

    RNS 9312170 ↗
  21. 18 Dec 25
    Issue of Equity
    RNS 9304923 ↗
  22. 08 Dec 25
    Holding(s) in Company
    RNS 9282746 ↗
  23. 28 Nov 25
    Total Voting Rights
    RNS 9262512 ↗
  24. 19 Nov 25
    Publication of Prospectus
    RNS 9244213 ↗
  25. 29 Oct 25
    Clinical Trial Update and Grant of Share Awards

    DSMB Clearance to Proceed to the Next Dose Level of HG-CT-1 in Adult Patients, Opening Pediatric Recruitment, and Grant of Restricted Share Units to Hemogenyx Team

    RNS 9200443 ↗
  26. 06 Oct 25
    Clearance to Initiate Pediatric Enrolment

    MD Anderson Clearance to Initiate Pediatric Enrolment in HG-CT-1 Clinical Trial

    RNS 9151440 ↗

Source: Investegate RNS archive. Quotes are short extracts. Not investment advice.